Appello: APLO-1201 - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
Phase 2, double-blind, placebo-controlled study to evaluate the effectiveness of two doses of AP-472 as adjunctive therapy to levodopa in Parkinson's disease (PD) participants with motor fluctuations
Principal Investigator
Kathryn P.L. Moore, MD, MSc
Neurologist
Protocol Number
IRB:
PRO00119836
NCT:
NCT07432958
Phase
Phase II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment